Data as of Nov 21
| +0.20 / +1.94%|
The 3 analysts offering 12-month price forecasts for MusclePharm Corp have a median target of 18.00, with a high estimate of 22.00 and a low estimate of 16.00. The median estimate represents a +71.43% increase from the last price of 10.50.
The current consensus among 2 polled investment analysts is to Buy stock in MusclePharm Corp. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.